They Renamed PCOS. Here Is Why Hypermobility Should Be Next.

On May 12, 2026, an international panel announced that Polycystic Ovary Syndrome (PCOS) would be formally renamed. After 14 years of campaigning involving more than 14,000 patients and health professionals across six continents, the condition now has a new name: Polyendocrine Metabolic Ovarian Syndrome, or PMOS.

For anyone who has spent years explaining that their body works as a connected system, this story sounds incredibly familiar.

It is the same story told by people with hypermobility who wait two decades for a diagnosis. It is the same story told by autistic adults whose chronic pain gets dismissed as simple anxiety. It is the story of being told you do not fit the textbook, while knowing all along that the textbook is incomplete.

This piece is about why that name change matters. But more than that, it is about what the long road to PMOS reveals about how medicine handles complex chronic conditions, especially those affecting women, and why that pattern will feel deeply recognizable to anyone in the hypermobility and neurodivergent communities.

1. Why the Name PCOS Stopped Working

The original name placed heavy emphasis on ovarian appearance, despite the condition being understood for decades as an endocrine and metabolic disorder. The term was repeatedly recognized as misleading. The cysts seen on ultrasound are not actually cysts at all, but arrested follicles. Yet, the name persisted.

Many patients did not have polycystic ovaries. Others experienced the most severe impact through symptoms completely unrelated to ovarian morphology:

• Insulin resistance and metabolic dysfunction

• Chronic inflammation and fatigue

• Hormonal dysregulation and mood disturbances

• Sleep disruption

• Elevated risk for type 2 diabetes and cardiovascular disease

The new name, Polyendocrine Metabolic Ovarian Syndrome, addresses three specific gaps:

Polyendocrine: Acknowledges multiple interacting hormonal disturbances across insulin, androgens, and neuroendocrine pathways.

Metabolic: Captures the inherent metabolic features including insulin resistance and cardiovascular risk.

Ovarian: Retains the connection to ovarian dysfunction without reducing the condition entirely to a reproductive disorder.

The Lancet publication noted that the previous term was inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and directly contributing to delayed diagnosis, fragmented care, and stigma.

2. Fourteen Years of Waiting: The Parallel to Hypermobility

A 2012 NIH expert workshop first raised the need to reconsider the name, followed by sustained international debate and patient advocacy over the next decade.

The eventual consensus shift took roughly 14 years from initial formal recognition to a concrete implementation strategy. That timeline becomes far more meaningful when placed alongside other chronic conditions with similar diagnostic delays: 

• hEDS Global Average: The diagnostic delay for hypermobile Ehlers-Danlos syndrome averages 22 years in global surveys.

• hEDS US Average: A 2026 study found a median delay of 10 years for hEDS diagnosis in the United States.

• HSD Average: For those with hypermobility spectrum disorders, the average wait is 17 years.

These are not just numbers. These are years of being told symptoms are normal. These are years of being referred from one specialist to another, watching research accumulate while clinical practice stays frozen.

For decades, patients with hypermobility were told joint pain was psychosomatic, fatigue was deconditioning, and dysautonomia was anxiety. For decades, autistic adults were told their physical pain was just sensory sensitivity or attention-seeking behavior.

The PMOS community went through the exact same cycle. Women were told their metabolic symptoms were stress, their fatigue was laziness, and their mood changes were hormonal exaggeration.

Online communities changed this. Patients began comparing experiences at scale and challenging frameworks that felt incomplete. That collective knowledge eventually pushed research forward, but clinical practice still lags behind.

3. The Know-Do Gap and What Still Needs to Improve

There is a technical term for what happened with PMOS: the knowledge translation gap or the 'Know-Do' gap. It is the gap between what research knows and what clinical practice does.

Historically, it takes an average of 17 years to move new evidence from publication into routine medical practice. This "know-do" gap prevents life-saving treatments from reaching patients and delays implementation of important health interventions. It hits hardest for conditions that are chronic, multisystem, and disproportionately affect women.

The PMOS renaming took 14 years. That is actually faster than average. That speed came from an unprecedented global consensus process involving 56 organizations and thousands of patients who refused to stop advocating.

Crucially, this is not just a theoretical name change. The international panel announced a formal three-year transition window to phase out the old terminology entirely, culminating in full clinical implementation for the 2028 International Guideline update. 

Here is what that means for the hypermobility and neurodivergent communities. The research showing the overlap between these conditions is still young. The evidence linking connective tissue disorders to autonomic dysfunction, mast cell activation, and neurodivergence is accumulating, but translation into clinical practice remains slow. Patients will keep being told their symptoms are unrelated. Care will stay fragmented.

That is not a failure of any single clinician. It is a systemic problem, and systems change slowly. Future progress will require several shifts:

• More interdisciplinary research and better clinician education around complex chronic illness.

• Earlier endocrine and metabolic screening alongside greater awareness of multisystem symptom presentation.

• Stronger integration between women's health, neurology, immunology, and autonomic medicine.

• Genuinely inclusive diagnostic frameworks that do not dismiss symptoms that fall between specialties.

For people with hypermobility and neurodivergence, the same gaps remain. Research shows that autistic individuals with hEDS continue to face systemic barriers, fragmented care, and clinicians who lack basic awareness of either condition.

4. What This Means for the ParaMotion Community

At ParaMotion, we work daily with individuals whose bodies do not fit into neat, isolated diagnostic boxes. Hypermobility, neurodivergence, PMOS, dysautonomia, and mast cell activation syndrome (MCAS) are not disparate conditions. They are deeply interconnected expressions of systemic dysregulation.

When we look closer at the intersection of metabolic health and connective tissue, the biological links become undeniable:

• The Glycation Effect: Metabolic insulin resistance alters how the body processes glucose, creating advanced glycation end-products (AGEs). These compounds structurally stiffen or weaken the extracellular matrix, directly impacting collagen health in hypermobile bodies.

  
  

• The Neuro-Endocrine Axis: Autonomic dysfunction (dysautonomia), which is exceptionally common in neurodivergent populations, fundamentally alters the body’s stress response, driving the exact chronic inflammation that exacerbates PMOS symptoms.

We approach movement therapy from a whole-body perspective because that is what the research increasingly supports, and it is what many patients have been describing for years. Hormones affect connective tissue. The nervous system affects metabolism. Inflammation affects everything.

The PMOS name change is a massive victory, but language is only the first step. The real work is in changing how care is delivered.

The language is shifting, but the larger challenge remains: building care models capable of recognizing complexity earlier and responding to it more coherently. That is the work we continue to do at ParaMotion.

How has your journey to diagnosis impacted how you look at your health? If you are looking for a movement practice that understands the intersection of hypermobility, neurodivergence, and systemic wellness, explore our programs at ParaMotion or share your story in the comments below.